Friday, December 3, 2010

Answered: Thirty Eight Questions About Hepatitis C




Part Four: Questions About Hepatitis C

Peppermint Patti’s FAQs in English (v. 10.1, 2015)
PEPPERMINT PATTI’s FAQs come out every year or two. Version 10.1 (2015, English) is 150 pages of answers to the questions most frequently asked (plus many less-frequently asked) about hepatitis C. It contains information about the hepatitis C virus (HCV), its treatment, and related complications.





Hepatitis C: Anemia And Other Side Effects During Treatment


Related Article : Preparing For Treatment


Side effects are seen in almost 80 percent of people treating with peginterferon and ribavirin. As patients we need to recognize these symptoms early on in order to avoid discontinuation or a dose reduction in therapy. Compliance to HCV treatment is an important factor for achieving SVR.


What we know is 100% compliance with the peginterferon and ribavirin regime always produces better results than 80 or 90% compliance.


From : Melissa Palmer, MDClinical Professor of MedicineDepartment of Hepatology


Importance of Adherence to HCV Regimens

Key Points

"Approximately 60% of patients with HCV in the United States adhered to prescribed therapy",''Indeed, studies have demonstrated that exposure to weight-based ribavirin vs fixed-dose ribavirin is associated with improved early virologic response and SVR rates"

'Reduction of the incidence and severity of treatment-induced anemia with erythropoietin has been shown to encourage adherence and to enable patients to remain on higher doses of ribavirin''

''Therefore, to improve adherence, practitioners must evaluate all HCV-infected patients at baseline and during therapy for psychiatric symptoms and initiate antidepressants or antipsychotics promptly, as needed.''




From the American College of Gastroenterology

Peginterferon suppresses the bone marrow and ribavirin
causes hemolysis. As a result, it is essential that
blood counts be assessed at regular intervals during
HCV treatment. When treatment is first initiated blood
counts should be assessed at a minimum of once
monthly until the hemoglobin, WBC, absolute neutrophil
count and platelet count are stable. However, some
physicians will assess blood counts more frequently, at
2 week intervals, until these values are stable. Liver
chemistries can be monitored less frequently but
for convenience are generally assessed at the same
frequency as hematologic testing. Thyroid function
should be assessed at baseline and at 3 month intervals
unless patients develop symptoms of either hypo- or
hyperthyroidism. Pregnancy testing should be performed
by females who are capable of conception at monthly
intervals.


Hepatitis C Treatment and Anemia

During your hepatitis C treatment period, you
will have your blood drawn on a regular basis to
check many lab values, including hemoglobin. It is
important to have the labs drawn when instructed
by your doctor’s office.

Why Your Body Needs Hemoglobin


Just like a car, your body needs fuel to run. Hemoglobin, or Hb,
is important because it transports oxygen in your blood to all
parts of your body. Think of the oxygen carried by hemoglobin
as the fuel your body needs to stay alive and run efficiently.
Hemoglobin is a substance found in your red blood cells
that carries most of your oxygen. Although other substances
in your body, such as water and plasma, also carry oxygen,
hemoglobin is unique because it can carry four times as
much oxygen throughout the body.


How Hemoglobin Fuels Your Body


Because Hemoglobin contains iron, it is an excellent vehicle
for transporting oxygen and carbon dioxide. When red blood
cells fill the air sacs of your lungs, they take up oxygen. The
hemoglobin in the red cells combines with the oxygen to form
a compound called oxyhemoglobin. When the red cells travel
through the rest of your body, they give up the oxygen to the
tissues. In the tissues, hemoglobin takes up carbon dioxide
(waste material) and releases it in the air sacs of the lungs.

The carbon dioxide is then exhaled.


What Causes Anemia

Anemia is caused by low levels of red blood cells, or
hemoglobin, in your blood. A severely anemic person’s blood
cannot carry enough oxygen to meet the needs of the body
tissues. As a result, over time the person becomes tired
physically and mentally, and feels cold.
When on interferon and ribavirin treatment for Hepatitis C, a
reduction in hemoglobin very commonly occurs and in most
cases, it is maintained at levels below the normal laboratory
ranges, returning to normal after treatment is completed or
stopped. Anemia is an expected side effect of treatment with
interferon and ribavirin.

In addition to anemia caused by interferon and ribavirin,
anemia can be caused by kidney disease, lack of vitamin B12
or folic acid in your diet, an inherited blood disorder such
as sickle cell anemia, blood loss from an injury or accident,
gastrointestinal bleeding, or lack of iron.


Symptoms of Anemia

Have you ever held your breath for longer than a minute? Do
you remember how you were afterward? With anemia, you
would feel tired all the time. Even extra sleep will not help
an anemic person feel better. If you are anemic, you may
experience:


• Extreme fatigue and weakness
• Feeling tired
• Difficulty sleeping
• Difficulty thinking clearly
• Headache
• Dizziness or fainting
• Cold
• Paleness


Treatment for Anemia

Your doctor will monitor your hemoglobin levels by looking at
your blood test results. It is not uncommon for hemoglobin
values less than normal to be followed closely without any
change in medication or other treatments. He may reduce the
dose of ribavirin. However, there may be a time when your doctor
discusses a separate treatment called Procrit® or Epogen® for
the anemia and the side effects you are experiencing.
Procrit® or Epogen® is identical to erythropoietin (e-RItH-ro-POIe-
tin), the substance your kidneys normally make. It stimulates
your bone marrow to make new red blood cells. As a result,
more red blood cells can carry oxygen to the body, which may
increase your energy level and provide relief from the symptoms
of anemia, such as fatigue and shortness of breath. Procrit®
or Epogen® is available only by prescription. It is an injection
given underneath the skin like the injection of interferon you are
already receiving. Your doctor will tell you what dosage is right
for you. Studies have shown that you feel better during hepatitis
C treatment when taking these medicines.

Precautions

Before administering this medication, tell your doctor or
pharmacist if you are allergic to epoetin, human albumin, or
any other drugs. Always tell your doctor and pharmacist what
prescription and non-prescription medications you are taking,
including vitamins.

Administering Your Medication

Store the medication in the refrigerator. Do not allow the
medication to freeze. Take your next dose from the refrigerator
1 hour before using it; place it in a clean, dry area to allow it
to warm to room temperature. Avoid shaking the vial. Use a
vial only once, and do not reenter a needle into a vial. Discard
unused portions and outdated medication.

Before you administer your medication, look at the solution
closely. It should be clear and free of floating material.
Observe the solution container to make sure there are no
leaks. Do not use the solution if it is discolored, if it contains
particles, or if the container leaks. Use a new solution and
contact the pharmacy to report the damaged one.
It is important that you use your medication exactly as directed.

Do not change your dosing schedule without talking to your
doctor’s office. Do not stop your therapy on your own because
your ability to continue interferon and ribavirin could be
hampered. Call the doctor if you have any questions or concerns.


Side Effects

Side effects are uncommon but they can occur. Procrit® or
Epogen® sometimes causes a flu-like reaction with chills,
shivering, sweating, muscle aches, and bone aches. These
effects may appear 1–2 hours after an injection and usually go
away within 12 hours. They may go away during treatment as
your body adapts to the medication. However, tell your doctor if
any of these problems continues or worsens. Your doctor should
carefully monitor your blood pressure and hemoglobin for rapid
increases, which should be avoided. An extremely rare side
effect of Procrit® or Epogen® is to cause your red blood cells to
stay very low. Your doctor will monitor your blood to detect this.
Complete Product Information is available from your
pharmacist. The information will provide you with a complete
list of possible side effects and other details concerning the
medication


Flu-like Symptoms

(fever, chills, headaches, fatigue, muscle aches)

• One hour before your injection, take 2
regular strength acetaminophen (Tylenol®
or generic), or 2 ibuprofen (Advil®, Motrin®,
or generic). You may repeat every 4-6 hours
after your injection as needed.


• Do not take more than 2000 mg of
acetaminophen in 24 hour period.
• Do not take more than 1600 mg of
ibuprofen in 24 hour period.
• *If you take both acetaminophen and
ibuprofen in the same 24 hour period,
do not take more than half the maximum
daily dose listed above for each product.*
• Increase your daily intake of fluids (nonalcoholic
and non-caffeinated).

We recommend 8–10 glasses (8 oz.) of
water or other clear beverages each day.


• Take pegylated interferon injections in the
evening or at bedtime to sleep through
most of the flu-like symptoms.

Depression & Irritability

Depression is the most common psychiatric disorder
precipitated by peginterferon and ribavirin therapy.
Many patients develop depression as a side effect of
insomnia and severe fatigue associated with anemia.
Treating insomnia and enabling these patients to
obtain better sleep significantly improves depression
in many patients. Many anti-depressants enhance
sleep as a side effect and these agents are very
effective in treating depression in patients receiving
peginterferon and ribavirin with insomnia. In patients
whose depression appears unrelated to insomnia, other
antidepressive agents will likely be more effective.


(signs of depression include feelings of deep and
constant sadness, hopelessness, crying, major
changes in mood, loss of interest in things you
enjoy, trouble sleeping/concentrating)


• Avoid stressful situations if possible, and
learn relaxation techniques.
• Include light exercise in your daily routine.
• Become a volunteer for someone less
fortunate than yourself.
• Seek professional help. Be sure to
notify the clinic if these feelings persist,
there may be medications available by
prescription to help you.
• If you experience thoughts of harming or
killing yourself or others, call the clinic
immediately!


Mild Hair Thinning

• Shorter hairstyles may reduce hair loss.
• Don’t wash your hair excessively. If you
wash your hair daily, try switching to every
other day.
• Avoid using blow dryers and chemical
treatments on your hair.
• Hair growth will return after treatment is
discontinued.


Loss of Appetite

(10-15 lb. weight loss is common)

• Eat frequent small meals throughout the
day, even if you aren’t hungry. “Grazing”
rather than 3 large meals is often helpful.
• A light walk or short exercise before meals
can increase appetite and decrease nausea.
• Try protein powder shakes, or dietary
supplements (Ensure®, Boost®, Sustacal®,
Slim Fast®) in addition to regular meals.
• Eliminate any metallic taste in your mouth
by brushing regularly. Some people have
found that eating a small amount of dark
chocolate, yogurt, or honey before a meal
helps to reduce the metallic taste. Fresh
lemon in ice water is also helpful.
Nausea, Vomiting, and Diarrhea
• Drink plenty of fluids (non-alcoholic and
non-caffeinated).
• Taking your ribavirin with food may
reduce nausea.
• For occasional diarrhea, switch to bland
foods such as bananas, rice, applesauce,
and dry toast or crackers until diarrhea
resolves. Then gradually return to a
normal diet.
• Take over-the-counter medications for
nausea and diarrhea. If these do not help,
call the clinic for prescription medications.
• Any vomiting or diarrhea lasting more than
3 days should be reported to the clinic


Dry, Itchy Skin and Mild Rash


•Take short, warm (not hot) baths or
showers. Use a moisturizing soap (ie,
Dove® or Aveeno®).
• Use unscented skin lotions. Eucerin®,
Curel®, and LacHydrin® creams are very
helpful.
• Be sure to use sunscreen (at least SPF
15), as patients on medication are more
prone to burning.
• Try over-the-counter hydrocortisone creams
or Benadryl® spray.
• If itching persists, call the clinic for further
advice and/or prescription medications.
Skin Irritation at the Injection Site
• Painless, red irritation of the skin at the
site of the injection is common.
• This resolves on its own within 7-10 days.
To minimize this reaction, remember to
rotate the site of your injections.

Chest Pain

• Chest pain is an uncommon side effect of
the medication that should be reported
immediately to the clinic. Proceed to the
nearest emergency room if necessary.
Insomnia (inability to sleep)

• The medicines for hepatitis C can sometimes
interfere with your normal sleep
cycle. Getting a good night’s rest will help
with some of the flu like symptoms. If you
have trouble sleeping, call your clinic for
suggestions/medications.


Chronic Diseases Exacerbated or Precipitated by Antiviral Therapy

Several chronic conditions can be exacerbated or precipitated by peginterferon and ribavirin therapy. Some of these diseases may require that the patient be seen by a specialist in that area to assess the risk of HCV treatment on that disease and to treat the disease if an exacerbation occurs

Cardiovascular disease

As the hemoglobin declines, patients with coronary artery
disease may experience angina. Patients with known
coronary artery disease may wish to consult a cardiologist
prior to initiating treatment.

Seizures

Peginterferon reduces the seizure threshold. Patients with
a history of seizures may develop seizures after initiating
peginterferon treatment even if their seizure disorder had been
controlled for many years. Patients with a history of seizures
should be seen by a neurologist prior to initiating HCV
treatment and possibly on a regular basis during treatment.

Psychiatric disease

Peginterferon may precipitate and exacerbate many psychiatric
disorders. The most common psychiatric symptom experienced
by patients receiving peginterferon is depression.
This can develop even in patients without a prior history
of depression. Depression may be so severe that suicidal
thoughts may develop. Uncontrolled psychiatric disease is
a contraindication to utilizing peginterferon. Patients with
active but well controlled psychiatric disease should see a
psychiatrist prior to initiating peginterferon and for at least
several weeks after treatment is initiated to identify patients
who might need adjustment of psychiatric medications.

Retinal disease

Peginterferon has been reported to cause blurred vision and
changes to the vascular supply of the retina. Patients with
hypertension and diabetes mellitus are at increased risk
for retinal disease. It is recommended that patients with a
history of hypertension and/or diabetes mellitus undergo a
retinal examination prior to initiating peginterferon therapy.
However, not all experts agree this is necessary and would
only consult an ophthalmologist if a patient developed visual
changes during treatment.

Diabetes mellitus

Treatment with peginterferon may precipitate the onset
of diabetes mellitus or alter the patient’s eating patterns
and glucose utilization and lead to either hypo- or
hyperglycemia in a patient with previously controlled
diabetes. Patients with insulin resistance, type-2
diabetes and an elevated hemoglobin-A1-C have been
shown to have a lower SVR during treatment. For this
reason, patients with poorly controlled diabetes and
markedly elevated hemoglobin A1-C should probably
see an endocrinologist for better diabetes management
before initiating treatment.

Autoimmune disorders

Peginterferon may exacerbate as well as precipitate
autoimmune disorders. As a result, autoimmune diseases
are generally considered relative contraindications to HCV
treatment. Many patients with chronic HCV have severe
myalgias, arthralgias and a positive rheumatoid factor. HCV
is known to cause these findings in the absence of true
rheumatoid arthritis and many patients with chronic HCV are
incorrectly diagnosed with rheumatoid arthritis when this was
simply secondary to chronic HCV. Eradication of HCV RNA
in these patients is associated with resolution of arthralgias
and loss of rheumatoid factor. Having the patient see a
rheumatologist to clarify if the patient has true rheumatoid
arthritis or a reactive arthritis secondary to HCV may be
necessary in some patients

Personalized medicine : Genetic makeup to predict the risk of disease or response to a drug


Description
Personalized medicine centers on being able to predict the risk of disease or response to a drug based on a person’s genetic makeup. But a study by scientists at Washington University School of Medicine in St. Louis suggests that, for most common diseases, genes alone only tell part of the story. Their research shows the environment interacts with DNA in ways that are difficult to predict, even in simple organisms like single-celled yeast.
.
“Measuring the environment becomes crucial when we try to understand how it interacts with genetics,” Cohen says. “Having a particular genetic variant may not have much of an effect but combined with a person’s environment, it may have a huge effect.”
.
.
The Gene-Environment Enigma
Released: 12/3/2010 9:00 AM EST Source: Washington University in St. Louis
Newswise — Personalized medicine centers on being able to predict the risk of disease or response to a drug based on a person’s genetic makeup. But a study by scientists at Washington University School of Medicine in St. Louis suggests that, for most common diseases, genes alone only tell part of the story.

That’s because the environment interacts with DNA in ways that are difficult to predict, even in simple organisms like single-celled yeast, their research shows.
“The effects of a person’s genes – and, therefore, their risk of disease – are greatly influenced by their environment,” says senior author Barak Cohen, PhD, a geneticist at Washington University School of Medicine. “So, if personalized medicine is going to work, we need to find a way to measure a human’s environment.”
The research is available online in PLoS Genetics.
To understand gene-environment interactions at the most basic level – at the individual DNA letters that make up the genetic code – the researchers turned to a model organism, the yeast Saccharomyces cerevisiae, culled from North American oak trees and vineyards, where it grows naturally. They asked whether growing the yeast in different environments would influence the rate at which the yeast produce spores, a form of sexual reproduction.
This complex trait is heavily influenced by genetics, Cohen’s earlier research has shown. In a study published in 2009 in Science, he determined that just four DNA variants, called single nucleotide polymorphisms (SNPs), account for 90 percent of the efficiency with which yeast produce spores.

In that study, the researchers noted that yeast from oak trees produced spores with 99 percent efficiency; the vineyard strains were far less efficient, at 7 percent. Then, they put each combination of the four SNPs in both the oak and vineyard strains, to determine how the genetic variants interacted with one another.
The researchers showed that the four variants “interacted like crazy such that the combined effects of any four variants were always larger than the sum of their individual effects,” Cohen says.

By developing a statistical model to account for the genetic interactions, they could genotype any combination of the four SNPs in either strain of yeast and predict with a high level of confidence their effect on sporulation.

But in that study, the yeast were grown in the same environment – glucose.
In the current study, the scientists grew the two yeast strains with all 16 combinations of four SNPs in different simple sugars: glucose, fructose, sucrose, maltose, raffinose, grape juice, galactose and a combination of sucrose, glucose and fructose.
“These were all mono- or di-saccharides, so the environments are not radically different from one another,” Cohen explains. “It’s not like we heated up the yeast or froze them, added acids or put them in a centrifuge. We simply changed the carbon source and measured the effects of those four SNPs in the different environments.”
Surprisingly, the researchers found that the effects of the four SNPs on spore production were dramatically different in the different environments. The effects of different combinations of SNPs in one environment were not an accurate predictor of the effects of those same SNPs in other environments.

For example, one combination of the four SNPs increased sporulation efficiency by 40 percent in glucose, but that same SNP combination increased efficiency by 80 percent when the yeast were grown in raffinose.

Indeed, the relative importance of particular SNPs and their interactions were not constant but varied with the genetic background of the yeast strain and the environment.
“Having a particular combination of SNPs was never a great predictor,” Cohen says. “If we didn’t know the environment in which the yeast were grown, we could not accurately predict the effect of the SNPs on producing spores. And if we can’t make accurate predictions about the way environment influences complex traits in yeast, then it will be exceedingly difficult to do so in people.”

The new research raises many questions: what is a human’s environment and how can it be measured? Is the environment a person lived in during childhood important or the environment he lives in now?

Cohen suspects that any environment that matters is likely to leave a measurable molecular signature. For example, eating a lot of fatty foods raises triglycerides; smoking raises nicotine levels; and eating high-fat, high-sugar foods raises blood sugar levels, which increases the risk of diabetes. The key, he says, is to figure out what are good metabolic readouts of the environment and factor those into statistical models that assess genetic susceptibility to disease or response to medication.

“Measuring the environment becomes crucial when we try to understand how it interacts with genetics,” Cohen says. “Having a particular genetic variant may not have much of an effect but combined with a person’s environment, it may have a huge effect.”
Cohen says he’s not hopeless when it comes to personalized medicine. As scientists conduct ever-larger studies to identify rare and common variants underlying diseases such as cancer, diabetes and schizophrenia, they will be more likely to uncover variants that have larger effects on disease. Even then, however, a person’s environment will be important, he adds.
The research was funded by the National Science Foundation.
Gerke J, Lorenz K, Ramnarine S, Cohen B. Gene-environment interactions at nucleotide resolution. Sept. 2010. PLoS Genetics.

Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked fourth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.

Liver Cancer:Peregrine Initiation Of Phase I/II trial bavituximab in combination with sorafenib.

Peregrine Announces Initiation of Phase I/II Investigator-Sponsored Trial in Liver Cancer
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced the initiation of an investigator-sponsored trial (IST) for patients with advanced hepatocellular carcinoma (HCC), or liver cancer. This Phase I/II trial will treat patients with Peregrine's investigational monoclonal antibody bavituximab in combination with sorafenib.

"Our research has demonstrated that sorafenib increases the exposure of the highly immunosuppressive molecule phosphatidylserine (PS) on tumor vasculature, providing more of a specific target for bavituximab," said Adam C. Yopp, M.D., lead investigator of this trial and assistant professor of surgery at the University of Texas Southwestern Medical Center. "We are eager to determine if combining the growth-blocking mechanisms of sorafenib with the vascular-targeting and immune-reactivation mechanisms of bavituximab offers additive anti-tumor effects for patients with HCC."

Currently, Peregrine's bavituximab is being evaluated in combination with chemotherapy in multiple Phase II trials in non-small cell lung cancer and advanced breast cancer, as well as a Phase Ib trial for hepatitis C virus (HCV) and HIV coinfection.

"In prior studies, bavituximab has demonstrated broad therapeutic potential in multiple oncology indications," said Marvin R. Garovoy, M.D., head of clinical science at Peregrine Pharmaceuticals. "Our IST program is designed to provide valuable clinical data on bavituximab's potential use in different therapeutic combinations and indications. We also expect to further clarify details of bavituximab's multiple mechanisms of action, and to identify specific biomarkers that could ultimately help to measure and predict bavituximab's potential anti-tumor and immunostimulatory effects. We look forward to collaborating with Dr. Yopp and his team, as well as other investigators who have applied for our program."

About the Phase I/II HCC Trial
In this Phase I/II non-randomized, open-label trial, patients with advanced HCC will receive bavituximab weekly and sorafenib (400 mg) twice daily, until disease progression or toxicity. Phase I of the trial is dose escalation (0.3, 1 or 3 mg/kg) to determine the maximum tolerated dose (MTD) and Phase II is expansion of the study at the MTD. Approximately 50 patients will be enrolled in this trial.

Primary objectives are to determine the MTD of bavituximab in patients with advanced HCC treated with sorafenib and the radiographic median time to progression. Secondary objectives include response rate, progression free-survival, overall survival, safety and tolerability. Further information about this trial is available at PeregrineTrials.com and University of Texas Southwestern Medical Center Clinical Trials, and will be available at ClinicalTrials.gov.

About Peregrine's Investigator-Sponsored Trials (IST) Program
Peregrine's IST program offers oncologists the opportunity to conduct clinical trials using bavituximab in the following indications:

Breast cancer
Hepatocellular carcinoma
Brain cancer
Prostate cancer
Pancreatic cancer
Non-small cell lung cancer
Colorectal cancer
Melanoma
Fibrosarcoma
Renal cancer
Urinary bladder cancer
Hodgkin's lymphoma
Ovarian cancer

To apply for Peregrine's IST program, please visit http://www.peregrineinc.com/pipeline/investigator-sponsored-trials.html.

About Hepatocellular Carcinoma (HCC)
According to the National Cancer Institute, primary liver and bile duct cancers are the sixth most common cause of cancer death in men, and ninth most common in women. Approximately 24,000 new cases of these two cancers are expected to be diagnosed this year in the United States, with approximately 19,000 deaths attributable to these forms of cancer. The most common risk factor for liver cancer is chronic hepatitis C virus (HCV) or hepatitis B virus (HBV) infection. Currently approved treatment options for HCC are surgery, radiation, chemotherapy, targeted therapeutics, tumor ablation, and tumor embolization.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results from investigator-sponsored trials will not be consistent with results experienced in earlier clinical trials and preclinical studies, the risk that investigators may experience delays in patient enrollment, risk that results may not support registration filings with the U.S. Food and Drug Administration, and the risk that Peregrine may not have or raise adequate financial resources to complete the planned clinical programs. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2010 and the quarterly report on Form 10-Q for the quarter ended July 31, 2010. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Hepatitis C : Morning News

Drinking More Coffee Linked to Improved Response to Hepatitis C Treatment
SUMMARY: Higher coffee consumption was associated with greater likelihood of response to hepatitis C treatment, according to data reported at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) in Boston. In the HALT-C trial, which looked at prior non-responders with advanced liver disease, people who drank more coffee were more likely to achieve early and sustained virological response to pegyalted interferon plus ribavirin.

Alcohol and Diabetes Increase Risk of Liver Disease Progression in Hepatitis B Patients
SUMMARY: Older patients and men with chronic hepatitis B virus (HBV) infection were more likely to progress to liver cancer, decompensated cirrhosis, and liver-related death, while Asian patients had lower progression rates, according to an analysis of Kaiser Permanent members presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) in Boston. Diabetes and heavy alcohol use also predicted poor outcomes.

Only The Rich Can Get Organ Transplants Now in Arizona
You know what should definitely be the last thing that states should ever cut from their budgets? Money for life-saving organ transplants. In Arizona, cuts to state medicaid have literally stolen organ transplants from sick poor people.

The six degrees of Steve Cohen
Posted by
Duff McDonald, Contributing Editor
December 3, 2010 10:44 am
He's the man with the bulls-eye on his head, yet the Feds can't quite seem to hit it. It's beginning to look like it's riskier to be associated with the hedge fund giant than it is to be Steve Cohen himself.
Chip Skowron, FrontPoint Partners
The Feds have charged French doctor Yves Benhamou with passing information about trials for hepatitis C drug Albuferon to Skowron, a former SAC analyst. Skowron has been placed on leave and FrontPoint is closing its health-care funds.


IncellDx molecular tests for diseases are cheaper, faster
IncellDx Inc. is trying to make that knowledge actionable. The Palo Alto startup combines molecular diagnostics with cellular analysis and focuses on HIV, AIDS, HPV, cervical cancer, hepatitis, organ transplant infections, breast cancer and ovarian cancer

Sixth hepatitis B death reported at N.C. assisted living center
There has been a sixth reported death in connection with an outbreak of hepatitis B at a North Carolina assisted living center.Public Health officials in North Carolina have announced that a former resident of GlenCare of Mount Olive died on November 23, according to WITN.com. Officials have not released the cause of death, but the officials acknowledge that the woman was diagnosed with hepatitis B in October during the screening of residents at the facility.Additional testing revealed that at least two other residents have antibodies to the disease, which suggests a possible infection, but neither was diagnosed and both have since recovered, WITN.com reports

Kadmon Pharmaceuticals Launches Topotecan for Injection
Kadmon Pharmaceuticals announced today that Three Rivers Pharmaceuticals, a Kadmon Company, has received approval from the US Food and Drug Administration (FDA) to market Topotecan Hydrochloride for Injection, 4 mg (base)/vial, the generic version of GlaxoSmithKline’s Hycamtin®. Kadmon’s Topotecan for Injection is now available for shipment.
Topotecan for Injection is indicated for small cell lung cancer sensitive disease after failure of first-line chemotherapy, and is also indicated for use in combination therapy with Cisplatin for stage IV-B, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy. Topotecan for Injection had U.S. sales of approximately $157.1 million in 2009, according to IMS Health.

Other Health News

Risk Of Death Increases In IBD Patients With Hospital-Acquired Infections
03 December 2010Death and length of stay are increased among hospitalized inflammatory bowel disease (IBD) patients who develop hospital-acquired infections, according to a study in Clinical Gastroenterology and Hepatology, the official...
[read article]

Cancer Prevention Coalition: Varmus is Unqualified to Lead the War against Cancer
The following is an opinion editorial provided by Samuel S. Epstein, M.D., Chairman of Cancer Prevention Coalition, and his colleagues:
On October 22, 2010, Senator Chuck Grassley, ranking member of the Senate Finance Committee, wrote to Dr. Harold Varmus, who was appointed director of the National Cancer Institute (NCI) by President Obama three months previously. The Senator raised questions on the amount of "sponsored travel," sometimes a dozen or more trips a year and almost exclusively to international conferences paid for by outside organizations or companies, taken in recent years by "numerous NCI employees, notably senior leadership." According to ScienceInsider, many of the 16 scientists involved took at least 10 trips a year in 2008, 2009, and 2010. One of the frequent fliers took 33 trips in 2008 and 2009, while another took 11 from October 2008 to March 2009.

Scientists Propose New International Cancer Effort Akin to Human Genome Project
ScienceDaily (Dec. 2, 2010) — Scientists are proposing an international effort, on the scale of the Human Genome Project (HGP), to identify all the proteins present in cancer cells. HGP was the international scientific research project that identified and mapped all the genes in humans.

Stem Cells
Research Scientists Home In On Chemicals Needed To Reprogram Cells
03 December 2010For Immediate Release Scripps Research Institute scientists have made a significant leap forward in the drive to find a way to safely reprogram mature human cells and turn them into stem cells, which can then change into...
[read article]

Scripps Research Scientists Home In On Chemicals Needed To Reprogram Cells
03 December 2010Scripps Research Institute scientists have made a significant leap forward in the drive to find a way to safely reprogram mature human cells and turn them into stem cells, which can then change into other cell types, such as...
[read article]

TAU Uncovers Muscle-Stem Cell Mechanism In Aging
03 December 2010Working out can help you shed pounds - but that's just the beginning. New research from Tel Aviv University has found that "endurance exercises," like a Central Park jog or a spinning class, can make us look younger..
.[read article]

Treating a life-threatening cancer of the bile duct by performing a liver transplant

Liver transplant for bile duct cancer improves survival

SCOTTSDALE, Ariz. – In what is a rare occurrence for all but a handful of U.S. medical centers, Mayo Clinic in Arizona is treating a life-threatening cancer of the bile duct by performing a liver transplant – an aggressive protocol that is exhibiting dramatic increases in survival rates, offering new hope for patients with this complex disease.

Mayo Clinic is one of only two liver transplant programs in the region of the U.S. that encompasses Arizona, California, Utah, Nevada and New Mexico performing liver transplants to treat Cholangiocarcinoma, a relatively rare bile duct cancer.

Moreover, Mayo Clinic is the only medical center doing living donor liver transplantation as a treatment protocol for Cholangiocarcinoma. In such a procedure, a healthy person donates half or slightly more of his or her liver to a family member or close friend who otherwise would be on a waiting list. Living donor liver transplants are performed because of the increased number of patients on the liver transplant waiting list and the shortage of available organs. An advantage for both the donor and recipient is that the surgeries can be performed at optimal times for both patients – and before the recipient becomes too ill to withstand the transplant surgery itself.
The living donor liver transplant program at Mayo Clinic in Arizona ranks in the top five programs in the nation and is the largest program in the Western U.S.

Cholangiocarcinoma is a malignant tumor of the bile duct (accounting for less than 1 percent of all cancers) that is most frequently found in the ducts located close to the liver. Such tumors are often resistant to treatment because the tumor can extend deep into the liver, making it difficult – if not impossible – to remove through conventional surgical methods. The conventional method for bile duct cancer is to remove or "resect" the tumor, which may require removing part of the liver. Survival rates have not been promising because of the potential spread of the cancer within the liver.

The major advantage of liver transplants to treat the rare bile duct cancer is that removal of the patient's entire liver also enables removal of the tumor itself, which in turn can mean a greater chance of longer-term survival. Until recently, such patients had few treatment options.
"By performing liver transplants for qualified patients with Cholangiocarcinoma, we are able to remove the entire liver, and therefore have more opportunity to remove the tumor itself, said David Douglas, M.D., Medical Director of Liver Transplantation at Mayo Clinic. "Patients have a much better prognosis in terms of living longer and a better quality of life."

Longer-term survival is also enhanced by the addition of radiation therapy and chemotherapy, a combined treatment that begins prior to transplantation. This protocol is administered to lessen the risk that the tumor could spread to lymph nodes or other areas.

"The complexities involved in treating Cholangiocarcinoma require a skilled, multidisciplinary team of experts to work toward the common goal of prolonged, disease-free survival for the patient," said Dr. Douglas. At Mayo Clinic, multiple review conferences are held, and patient clinics are staffed by providers from Hepatology, Transplant Surgery, Medical and Radiation Oncology.

Mayo recently performed two living donor liver transplants in one week for bile duct cancer, following comprehensive evaluation of both the donors and recipients as to their suitability for the living donor procedure.

###
To request an appointment at Mayo Clinic, please call 480-422-1490 for the Arizona campus, 904-494-6484 for the Florida campus, or 507-216-4573 for the Minnesota campus.

About Mayo Clinic
Mayo Clinic is a non-profit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit www.mayoclinic.org/about/ and www.mayoclinic.org/news .
###
About Mayo Clinic
Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of "the needs of the patient come first." More than 3,700 physicians, scientists and researchers, and 50,100 allied health staff work at Mayo Clinic, which has campuses in Rochester, Minn; Jacksonville, Fla; and Scottsdale/Phoenix, Ariz.; and community-based providers in more than 70 locations in southern Minnesota., western Wisconsin and northeast Iowa. These locations treat more than half a million people each year. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news.

For information about research and education, visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.

Thursday, December 2, 2010

Hepatitis C Best Of The Liver Meeting:Infectious Complications of Cirrhosis

The Best of The Liver Meeting® lets you catch up with what you missed at the meeting and enables you to revisit a session. All of the sessions are presented with audio and synchronized slide presentations.

Below is a list of The Best of The Liver Meeting® 2010 sessions.

Waiting For Hepatitis Debrief : Note The captured session has been delayed due to prepublication data issues and AASLD is working to rectify the issue.

In Case You Missed It :
Hans Popper Basic Science State-of-the-Art Lecture
Bile Acid Signaling: A Journey from the Nucleus to the Cell Membrane


Johan Auwerx, MD, PhD
Thomas E. Starzl Transplant Surgery State-of-the-Art Lecture
Hepatobiliary Neoplasia -- Is Transplantation the Answer?

Michael M. Abecassis, MD
Hyman J. Zimmerman Hepatotoxicity Lecture
The Good, the Bad, and the Ugly: Innate Immunity in Liver Injury

Gyongyi Szabo, MD, PhD
Leon Schiff State-of-the-Art Lecture
Genetics and Personalized Medicine for the Treatment of Hepatitis C

Added Dec 2

General Hepatology Update

Infectious Complications of Cirrhosis/Guadalupe Garcia-Tsao, MD

Iron Overload/Kyle Brown, MD

Vitamin D and Statins/Naga P. Chalasani, MD

Emerging Trends in Imaging Liver Disease


Imaging to Assess Progression of Chronic Liver Disease/Scott Reeder, MD, PhD

Imaging of Masses in Cirrhotic Liver/Bachir Taouli, MD

Imaging of Masses in Non-Cirrhotic Liver /Claude B. Sirlin, MD

Measuring HPVG Correctly/Juan Carlos Garcia-Pagan, MD

Global Forum

Understanding the Global Burden of Liver Disease/ Steven Wiersma, MD

North American Perspective/Hashem B. El-Serag, MD

European Perspective/Mark R. Thursz

Latin American Perspective/Martin Padilla, MD

Asian Perspective/Shiv K. Sarin, MD

African Perspective/Ayman Yosry, MD

Advances for Practitioners

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype I Infection
Donald M. Jensen, MD

Genetic Variation in IL28B Predicts Hepatitis C Treatment-induced Viral Clearance
Gary L. Davis, MD

Epidemiology of Hepatitis E Virus in the United States: Results from the Third National Health and Nutrition Examination Survey
Marc G. Ghany, MD

Nov 23 Update Hepatitis B Talking Slides From AASLD

http://www.aasld.org/lm/program/Pages/default.aspx


Anemia during Hepatitis C Treatment May Be A Good Sign

From Reuters Health Information

Anemia in Treated-HCV Patients Bodes Well for Sustained Virologic Response


NEW YORK (Reuters Health) Dec 01 - Anemia that develops in patients infected with hepatitis C virus (HCV) during treatment with peginterferon-alfa and ribavirin (PEG-IFN/RBV) may be a good sign, new research hints.

In a large study, researchers found that patients who developed anemia were more likely to achieve sustained virologic response (SVR) than those who did not, despite decreased RBV dosing following a decline in hemoglobin levels. In addition, the virologic relapse rate wasn't increased in patients who cut back on RBV dose.
These data "firmly underscore the recommendation for RBV dose reduction as the primary strategy for management of treatment-related anemia," write Dr. Mark S. Sulkowski, of Johns Hopkins University School of Medicine in Baltimore, and colleagues in the November 10th issue of Gastroenterology.

They also found that the use of erythropoiesis-stimulating agents (ESAs) minimized discontinuation of treatment in patients with early-onset anemia, leading to higher SVR rates in this subgroup.

Anemia is seen in up to 30% of treated HCV patients and often leads to RBV dose reduction and/or discontinuation of treatment, Dr. Sulkowski and colleagues note in their report.
However, because lower SVR rates have been reported in patients who cut back on RBV, "many clinicians and patients prefer to avoid this strategy and instead use ESAs (off-label) to improve anemia-related symptoms while maintaining RBV dose," the investigators note.
Nonetheless, "considerable uncertainty exists regarding the role of adjuvant ESAs during HCV treatment," they point out.

Dr. Sulkowski's team evaluated the relationship between treatment-related anemia, ESA use, and treatment outcomes in 3,023 treatment-naive patients with HCV genotype 1. All were treated for up to 48 weeks with a standard PEG-IFN/RBV regimen. ESAs were allowed for patients with hemoglobin levels less than 10 g/dL after RBV dose reduction.
Anemia occurred in 28.6% of study patients. Most of these patients lowered their RBV dose and 51.9% were given an ESA.

"Unexpectedly," the investigators say, the SVR rate was significantly higher in anemic patients than nonanemic patients (difference, +12% for anemic patients).

Moreover, SVR rates were associated with the magnitude of hemoglobin decrease. SVR rates were 43.7% in patients with an absolute hemoglobin decline greater than 3 grams per deciliter compared with 29.9% in those with a maximum decline of 3 grams per deciliter.
Patients with early-onset anemia (after 8 weeks or less of treatment) had significantly higher SVR rates with ESA use than those with later onset anemia. Those with early-onset anemia were also less apt to discontinue treatment due to adverse events (12.6% vs. 30.1%; P < 0.001).
ESAs didn't affect SVR or discontinuation rates among patients with late-onset anemia, suggesting that these patients are "not likely to benefit from adjuvant ESAs," the authors note.
The finding that RBV dose reduction wasn't associated with lower SVR rates is important, they say. "ESAs should not be used solely to avoid RBV dose reduction in anemic patients."
"Prospective, randomized controlled trials are needed to define the optimal role of adjuvant ESAs during HCV treatment regimens that include PEG-IFN/RBV," they conclude.
Gastroenterology. Posted November 10, 2010.
Abstract
http://www.medscape.com/viewarticle/733388